PolyNovo [ASX:PNV] shares are rising today after the biotech stock reported its indicative half-year trading results.
We review this week’s ASX news, from MNS and CPH getting caught up in ASIC probes to CBA shares tanking on their latest quarterly.
The Imugene [ASX:IMU] share price is up 6% following a supply agreement update. Imugene, the biotech stock, gained 600% over the last 12 months.
Up-and-coming biotech player Mesoblast [ASX:MSB] is on the up today. The regenerative medicine company announced some promising results from a Phase III drug trial from data that was shared at the American Heart Association’s annual ‘Scientific Sessions’, an exhibition of the latest findings and insights into all things heart health related.
It was an opinion piece discussing the recent listing (at the time) of Compass Pathways PLC [NASDAQ:CMPS]. A biotech stock with a very distinct twist...
‘Unprecedented change’ in the China infant formula market over the last 12 months led a2 Milk to alter its growth strategy, setting a medium-term goal of hitting NZ$2 billion in sales. a2 Milk Company [ASX:A2M] share price is currently trading for $6.09 a share, down 11%.
Tiny medtech stock Oneview Healthcare PLC [ASX:ONE] is on the up today. The ONE share price currently trading 6.98% higher at time of writing, paring back earlier gains of as much as 20.9% today.
The Creso Pharma [ASX:CPH] shares soared in early morning trade after the company announced its wholly-owned Canadian subsidiary, Mernova, secured over $800,000 in new purchase orders.
MGC Pharmaceuticals Ltd [ASX:MXC] share price is currently up 6.90%. The MGC Pharmaceuticals Ltd [ASX:MXC] announced that its distribution partner placed an order for 1,000 units of MXC’s CimetrA on an expedited basis.
MGC Pharmaceuticals said this marks the first time an epilepsy treatment containing THC and still undergoing clinical trials was approved by UK authorities for import. The news saw MGC Pharmaceuticals [ASX:MXC] shares jump 10% at the time of writing.